Some notes from the HQ (underwiter) CC:
Re 1067--
The P2b restensosis trial is partnered with SGP. Up to $189m milestones plus mid-teen royalty.
Small moledule inhibitor of the 'gene set' that normally responds TNF/receptor binding. It is synthetic, given 1 dose/day. Brought it from discovery to IND in 27 mos.
Indications are CAD, atherosclerosis, RA. It is also a 50-60% cholesterol lowering agent, and blocks LDL from becoming oxidized which contributes to CAD--so 3 vascualar protecting properties (anti-VCAM1, cholesterol lowering and anti-oxidant).
Numerous animal studies.
Tested 1 year in monkies. No tox given orally, daily. Showed 80% reduction in cholesterol, LDL up 30%, no evidence of atheroscerlosis in higher doses, some in lower doses. At 150mg/kg, the animals were blindly read as 'normal' by Quintiles (cross directorship here, incidentally). Animals livers were normal after 1 year.
P2 dosing finished. (missed dose mentioned, sorry). 6 weeks on, 6 weeks follow up. Reporting 4/01. Safety OK so far. Endpoint is 40-50% reduction in reclosure rate.
Re:4207
100% owned. RA. Pre-IND. Into clinic '01. Partner after P1 or P2.
Company plans on keeping CF and transplantation.
Prospectus suggests multiple drug opportunites from understanding intracellular signalling based on original inflammatory response.
--Wilder
Not touting, just contributing. |
